All In Biotech

Drug Trial Radar · NCT06387069

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

A Multicenter, Randomized, Open-Label, Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-306 vs. Salvage Chemotherapy Regimens in Patients With IDH1- and IDH2-mutated Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 316 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

316

Planned (sponsor's estimate)

Start

Apr 26, 2024

Primary completion

Dec 31, 2028

Study completion Sep 30, 2029

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Apr 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • HMPL-306 RegimenDrug

    Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.

  • Salvage Chemotherapy RegimenDrug

    Patients in this regimen will receive treatment with one of the following regimens, and the regimen will be selected by the investigator based on the patient's condition: * EA±Mitox regimen: etoposide injection 100 mg/m2, cytarabine injection 100-150 mg/m2, mitoxantrone injection 8 mg/m2 QD IV for 5 consecutive days (Days 1-5). * FLAG ± Ida regimen: G-CSF injection 300 mcg/m2 QD SC for 5 consecutive days (Days 1-5); fludarabine injection 30 mg/m2 QD IV for 5 consecutive days (Days 2-6); cytarabine injection 1000-2000 mg/m2 QD IV for 5 consecutive days (Days 2-6); idarubicin injection 10 mg/m2 QD IV for 3 consecutive days (Days 2-4). * LoDAC: -Cytarabine Injection 20 mg every 12 hours, subcutaneous or IV for 10 consecutive days (Days 1-10). * Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OSTime frame: Up to approximately 33 months

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

    Tianjin, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, China · Recruiting

  • Anhui Provincial Hospital(The First Affiliated Hospital of U STC)

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Recruiting

  • The First Affilated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Quanzhou First Hospital Affiliated to Fujian Medical University

    Quanzhou, Fujian, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital,Southern Medical University

    Guanzhou, Guangdong, China · Recruiting

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Affiliated Hospital of Zunyi Medical Univercity

    Zunyi, Guizhou, China · Recruiting

  • Baoding NO.1 Central Hospital

    Baoding, Hebei, China · Recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin First Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affilated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Recruiting

  • The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Union Hospital of China

    Wuhan, Hubei, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • People's Hospital of Hunan Province

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.